| |
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
| By Kevin Dunleavy Johnson & Johnson is laying off 231 employees in New Jersey and Bayer is cutting 57 positions in the state. The cuts follow other Big Pharma layoff rounds in the state. |
|
|
|
By Nick Paul Taylor Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients failed by existing options. Roche, Genentech’s parent company, also disclosed the acquisition of AntlerA. |
By Eric Sagonowsky No large pharma company has traversed this decade's ups and downs quite like Pfizer. As the company rolls ahead with a large restructuring campaign, some staffers in Ireland will soon feel the effects. |
By Nick Paul Taylor Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, which could receive a whopping $3.5 billion in milestones, disclosed the deal alongside details of a pipeline prioritization intended to extend its cash runway into the first half of 2026. |
|
Tuesday, October 8, 2024 | 10am ET / 7am PT In this webinar, you'll learn how companies can navigate the challenges of global expansion after their first regulatory approval. Discover how to make data-driven market entry decisions, launch efficiently, stay adaptable, and leverage commercial partners through case studies and real-life examples. Join us! 
|
|
By Zoey Becker Officials in Wilson, North Carolina, approved a $29.9 million incentive package for the company, including a grant worth up to $13.7 million. |
By Nick Paul Taylor Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate. |
By Nick Paul Taylor Moderna has suffered its second PMCPA rebuke in quick succession. Days after ruling Moderna had brought discredit on the industry, the U.K. self-regulatory body reached the same damning conclusion in a separate case. |
By Conor Hale The company’s millimeter-wave wristband stimulates the release of the endorphins to counteract the chronic condition and provide relief. |
By Kevin Dunleavy Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. With the nod, Dupixent becomes the first biologic treatment for COPD patients in the U.S. |
By Darren Incorvaia The COVID-19 pandemic made us acutely aware of how vulnerable our noses are. The nose is a gateway to infection for respiratory pathogens like influenza and SARS-CoV-2, but our options to shield our nasal passageways from disease are limited. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Fierce Healthcare's Heather Landi chats with former VA Secretary David Shulkin, M.D., to gain his insights on the future of healthcare policy. |
|
|---|
|
|
|
This comprehensive whitepaper explores the impact of strategic equipment lease financing for Pharma and Biotech companies. Learn how it can optimize cash flow, deliver access to mission-critical technology and equipment without large upfront capital investments, preserve equity, and enable growth opportunities. Download now. 
|
|
Whitepaper Cognizant, in partnership with Microsoft, have interviewed 200 medtech decision makers across the UK, Ireland, France, Germany and the USA to find out about what the future holds. A responsible AI framework is going to be key. Read our report to learn more. Sponsored by: Cognizant and Microsoft |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper Navigating the Path to Medication Adherence: Overcoming 8 Key Challenges Sponsored by: Quest Diagnostics |
Whitepaper Open up unexpected opportunities. This digital story offers pharma marketers proactive strategies for helping patients discover and switch to treatments, even if they aren’t actively looking to make a change. Sponsored by: Healthline Media |
Whitepaper Blood-based biomarker testing presents a promising solution to improve access to critical early risk assessment along with a pathway towards accelerated clinical trials for Alzheimer's Disease. Sponsored by: Quest Diagnostics |
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
